In:
Journal of Medical Virology, Wiley, Vol. 95, No. 3 ( 2023-03)
Abstract:
Novel immune escape variants have emerged as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) continues to spread worldwide. Many of the variants cause breakthrough infections in vaccinated populations, posing great challenges to current antiviral strategies targeting the immunodominance of the receptor‐binding domain within the spike protein. Here, we found that a novel broadly neutralizing monoclonal antibody (mAb), G5, provided efficient protection against SARS‐CoV‐2 variants of concern (VOCs) in vitro and in vivo. A single dose of mAb G5 could significantly inhibit the viral burden in mice challenged with the mouse‐adapted SARS‐CoV‐2 or SARS‐CoV‐2 Omicron BA.1 variant, as well as the body weight loss and cytokine release induced by mouse‐adapted SARS‐CoV‐2. The refined epitope recognized by mAb G5 was identified as 1148 FKEELDKYF 1156 in the stem helix of subunit S2. In addition, a human−mouse chimeric mAb was generated based on the variable region of heavy chain and VL genes of mAb G5. Our study provides a broad antibody drug candidate against SARS‐CoV‐2 VOCs and reveals a novel target for developing pan‐SARS‐CoV‐2 vaccines.
Type of Medium:
Online Resource
ISSN:
0146-6615
,
1096-9071
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
752392-0
detail.hit.zdb_id:
1475090-9